Mayr, Roman and Eckstein, Markus and Wirtz, Ralph M. and Santiago-Walker, Ademi and Baig, Mahadi and Sundaram, Ramesh and Carcione, Jenna Cody and Stoehr, Robert and Hartmann, Arndt and Bolenz, Christian and Burger, Maximilian and Otto, Wolfgang and Erben, Philipp and Breyer, Johannes (2022) Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guerin Immunotherapy. EUROPEAN UROLOGY, 81 (6). pp. 606-614. ISSN 0302-2838, 1873-7560
Full text not available from this repository. (Request a copy)Abstract
Background: Limited data are available on the prognostic and predictive value of fibroblast growth factor receptor alterations (FGFRa) relative to clinical outcomes in patients with non-muscle-invasive bladder cancer (NMIBC).Objective: To determine whether FGFRa may be clinically useful in stratifying for treatment response in a real-world cohort of patients with pT1 NMIBC treated and untreated with bacillus Calmette-Guerin (BCG) instillation therapy.Design, setting, and participants: A pooled dataset of matched clinical and genomic data (1992-2015) for pT1 NMIBC patients was assessed by the Bladder Cancer Research Initiative for Drug Targets in Germany consortium.Outcome measurements and statistical analysis: Key efficacy outcomes were recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS), which were estimated by Kaplan-Meier analysis, with hazard ratios calculated using a multivariate Cox proportional-hazard model.Results and limitations: In this retrospective study of 263 patients with high-grade NMIBC, at a median follow-up of 63 mo, 32% showed recurrence and 15% progressed to muscle-invasive bladder cancer. FGFRa were found in 43% of patients, including 39% mutations and 5.7% fusions. FGFRa were associated with lower rates of concomitant carcinoma in situ. Among patients with or without FGFRa, there was no significant dif-ference in PFS, RFS, and DSS in those who were BCG treated or BCG naive, or in the over-all population. Limitations include the retrospective design from a single-center setting. Conclusions: In patients with high-risk NMIBC, FGFRa were frequently observed. Patients with FGFRa who often exhibit recurrence/relapse after BCG treatment have a high unmet need. Patient summary: Our retrospective study suggests that fibroblast growth factor recep-tor alterations (FGFRa) occur frequently in non-muscle-invasive bladder cancer (NMIBC).Outcomes were similar with or without FGFRa in patients with NMIBC, both overall and for standard bacillus Calmette-Guerin (BCG) treatment. (c) 2022 The Authors.Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | FGFR3 MUTATIONS; UROTHELIAL CARCINOMA; GUIDELINES; BCG; PEMBROLIZUMAB; ASSOCIATION; PROGRESSION; RECURRENCE; BIOMARKER; NMIBC; Bacillus Calmette-Gu?rin; Bladder cancer; Fibroblast growth factor receptor; FGFR alterations; Non-muscle-invasive bladder; cancer |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Jan 2024 08:38 |
| Last Modified: | 26 Jan 2024 08:38 |
| URI: | https://pred.uni-regensburg.de/id/eprint/57462 |
Actions (login required)
 |
View Item |
